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Background: There are two main reasons for drug withdrawals at the various levels
of the development path – hepatic and cardiac toxicity. The latter one is mainly
connected with the proarrhythmic potency and according to the present practice is
supposed to be recognized at the pre-clinical (in vitro and animal in vivo) or clinical
level (human in vivo studies). There are, although, some limitations to all the above
mentioned methods which have led to novel in vitro – in vivo extrapolation methods
being introduced. With the use of in silico implemented mathematical and statistical
modelling it is possible to translate the in vitro findings into the human in vivo
situation at the population level. Human physiology is influenced by many
parameters and one of them which needs to be properly accounted for is a heart
rate which follows the circadian rhythm. We described such phenomenon
statistically which enabled the improved assessment of the drug proarrhythmic
potency.
Methods: A publicly available data set describing the circadian changes of the heart
rate of 18 healthy subjects, 5 males (average age 36, range 26–45) and 13 females
(average age 34, range 20–50) was used for the heart rate model development.
External validation was done with the use of a clinical research database containing
heart rate measurements derived from 67 healthy subjects, 34 males and 33 females
(average age 33, range 17–72). The developed heart rate model was then
incorporated into the ToxComp platform to simulate the impact of circadian
variation in the heart rate on QTc interval. The usability of the combined models was
assessed with moxifloxacin (MOXI) as a model drug.
Results: The developed heart rate model fitted well, both to the training data set
(RMSE = 128 ms and MAPE = 12.3%) and the validation data set (RMSE = 165 ms
and MAPE = 17.1%). Simulations performed at the population level proved that the
combination of the IVIVE platform and the population variability description allows
for the precise prediction of the circadian variation of drugs proarrhythmic effect.
Conclusions: It can be concluded that a flexible and practically useful model
describing the heart rate circadian variation has been developed and its performance
was verified.
Keywords: Heart rate, Circadian rhythm, Drugs cardiotoxicity, Regression modelling© 2013 Fijorek et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Fijorek et al. Theoretical Biology and Medical Modelling 2013, 10:7 Page 2 of 11
http://www.tbiomed.com/content/10/1/7Introduction
The withdrawal of several marketed drugs in the last decade, extensive re-labeling and a
high attrition rate, especially in the late stage of the drug development process, due to the
QT prolonging liability or TdP occurrence, have all established that proarrhythmia assess-
ment is a primary focus of regulatory bodies and the pharmaceutical industry. Thus careful
evaluation of the proarrhythmic potential of an investigated compound is an integral
element of the safety profile required for the approval of new drugs. There are several avail-
able models utilized for the assessment of drugs proarrhythmic potency at various levels of
drug development. The most commonly utilized and probably most reasonable pathways at
the non-clinical stage of development include in vitro models where the human ionic chan-
nels are heterologously expressed in non-human (i.e. XO, CHO) and human (i.e. HEK) cells,
in vivo/ex vivo animal studies where suggested species are used for the drug influence evalu-
ation at the cardiac level [1]. Novel techniques include the human stem cells derived
cardiomyocytes which, however, still lack the standard methodology [2]. At the early clinical
development stage the currently best available, yet costly and still not perfect thorough QT/
QTc clinical studies (TQTs) [3] are introduced to assess the QT prolongation by the candi-
date drug as compared with placebo and positive control. Currently there is a translational
gap in the quantitative extrapolation of the in vitro or animal studies’ outcomes to the
human situation. There are some rules of thumb [4] and decision trees [5] available to quali-
tatively (yes/no) predict QT prolongation potential in humans from in vitro assays, particu-
larly hERG channel inhibition assays. Moreover, there are no methods available to combine
in vitro assay information from multiple ion channels (INa, ICa, IKr, IKs) with human physio-
logical and demographic data to predict QT prolongation in humans. Physiologically based
in silico methods have a potential to bridge the translation gap between the in vitro electro-
physiological data gained from in vitro/ex-vivo studies and human QT liability. We have
recently developed a so called “bottom-up” in silico platform (ToxComp) which combines a
physiologically based electrophysiological model of human left ventricular cardiomyocytes
and a database of human physiological, genotypic and demographic data enabling the
prediction of the QT prolongation in humans based on the in vitro data [6,7]. ToxComp
has been previously used to predict QT prolongation liability of various compounds [8,9].
Until now ToxComp has predicted the absolute QT prolongation liability of a compound
assuming that the physiological parameter values are constant during the simulation, which
limited its ability to simulate clinical scenarios. With the addition of the circadian variation
model in ToxComp, the platform could potentially be employed in simulating clinical
scenarios before conducting clinical studies with an aim to optimize the designs and reduce
the chances of the failure of these costly and time intensive clinical studies.
A circadian rhythm is a biological process that displays an endogenous, entrainable
oscillation of roughly 24 hours [10]. In humans there are multiple physiological
processes which follow the circadian clock, including the heart rate (HR) [11]. In our
study context, however, the circadian rhythm of the heart rate is one of the most
important, since it may both influence the QT length and interfere with the drug effect
[12]. The mathematical and statistical modelling of the circadian variation of the heart
rate has been previously studied. Nakagawa and colleagues reported results of a study
which involved 44 (but 20 were included into the analysis phase) healthy individuals.
Subjects showed a significant circadian heart rate rhythm and based on the collected
data the authors proposed a cosinor model to describe such phenomenon, although
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the derived model [13]. Similar models, carrying identical limitations were proposed
independently by Massin and colleagues and Li and colleagues [14,15]. 57 healthy
children and 115 healthy, non-smoking adults were included respectively and the 24-hours
ECG measurements were used to derive the regression models. Probably the most detailed
analysis of the heart rate variation was presented by Bonnemeier et al. [16]. A large
group of 166 healthy individuals (81 females, 85 males) characterized by a wide
age range (20–70 years) was studied. The authors analysed differences of heart rate
circadian profiles for hourly aggregated measurements in a groups stratified by age
decades, separately for female and male subjects. The authors did not, however,
model their data. There is also a large number of publications where circadian
heart rate variation is discussed among various subpopulations (athletes, truck
drivers, welders) and diseases (myotonic dystrophy, angor patients) [17-20]. Although to
our best knowledge none of them proposed a model flexible enough and described in
enough detail to be directly applicable for the generation of a virtual human population
where heart rate is an attribute specific for every individual, and this was the main reason
we decided to develop a new model.Aims of the study
We aimed to develop and validate a model describing the gender and age dependent
circadian rhythm of the heart rate in European Caucasian healthy subjects. Additional
aims included quality and usability assessment of the model when incorporated into
the ToxComp platform. Its usability, in combination with other parameters describing
demographic (age, gender), physiological (i.e. cardiomyocytes characteristics, plasma ions
concentration) and genetic variability in a population, was tested in the virtual clinical trial.Materials and methods
PhysioNet data set description
The analyzed data set was obtained from the PhysioBank, which is an archive of
digitized sets of data reflecting physiological signals. The data warehouse contains over
50 various freely available databases, and for modelling purposes the MIT-BIH Normal
Sinus Rhythm Database was used [21]. There were a total of 18 subjects, 5 males (average
age 36, range 26–45) and 13 females (average age 34, range 20–50). For each subject up
to 24 hours of RR recordings were available. Subjects, on average, had 94,440 individual
RR measurements (range 73,300-115,900). In order to decrease the significant computa-
tional burden it was necessary to reduce the number of RR measurements per subject. RR
averaging in one-hour, half-hour and 15-minute ‘time windows’ was found inadequate
due to its variability reduction property. Stable results were obtained after sampling RR
measurements every 1 minute.Validation data set
Model validation was performed with the use of a completely independent data set. Data
was derived from Cracow’s clinical research database (1st Department of Cardiology and
Hypertension, Jagiellonian University Medical College). There were a total of 67 healthy
subjects in the validation data set, 34 males and 33 females (average age 33, range 17–72).
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appropriate cuff size were programmed to obtain readings every 15 minutes from 08.00 to
22.00 and every 30 minutes from 22.00 to 08.00. Each reading included systolic/diastolic
blood pressure, mean arterial pressure and heart rate. Subjects, on average, had 71 heart
rate measurements (range 35–99). RR interval length was calculated based on the heart
rate measurement results.
Model usability testing
To test the usability of the implemented circadian rhythm model within the ToxComp
platform, we have chosen moxifloxacin (MOXI), the most commonly used positive
control in TQT studies as the model compound. The ToxComp system was used to
simulate the drugs triggered ECG modification. The ToxComp platform combines
a physiologically based electrophysiological model of human left ventricular
cardiomyocytes (ten Tusscher - TNNP) and a database of human physiological,
genotypic and demographic data enabling the prediction of the QT prolongation in
humans based on the in vitro data [7,22]. To account for the heterogeneities in
ionic currents between endocardial, midmyocardial and epicardial cells 1D fibre
paced at the epicardial side was constructed. The 50:30:20 distribution of the endo-,
mid- and epicardial cells was used together with a diffusion coefficient equal to
0.0016 cm2/ms. The Forward Euler method was used to integrate model equations.
Integration results were used to calculate a pseudo-ECG. First and last QRS were
excluded from the pseudo-ECG. A space step and a time step were set to Δx=0.01 mm
and Δt=0.01 ms, total simulation time was set to 10,000 ms.
To account for the drugs triggered ionic currents modifications a specific equation
describing the current of interest was multiplied by the inhibition factor accordingly to
the in vitro values provided by the literature search, which described the concentration
dependent ionic current inhibition. The inhibition factor was calculated with the use of
the Hill equation [Equation 1].
Inhibition Factor ¼ 1
1þ IC50=DRUG CONCENTRATIONð Þn ð1Þ
where:
IC50 - concentration responsible for the 50% inhibition of the ionic current
n - Hill equation parameter
DRUG CONCENTRATION - active drug concentration [μM]
The population variability of other parameters was mimicked by applying the virtual
population generator as described previously [23,24]. The circadian heart rate variability
was introduced into a simulation by the use of the model described below.
3.8 μM of MOXI was used for the operational concentration, mimicking the average
maximum free plasma concentration (Cmax) after a 400 mg oral dose by correcting the
total Cmax concentration obtained from the available literature with human plasma pro-
tein binding [25,26]. The IC50 values for various cardiac ion channels were obtained
from the tox-database.net system and are presented in Table 1 [27]. For the simulation
studies only IKr data was used (with Hill equation parameter n = 1) since for the tested
MOXI concentration INa and ICa inhibition were negligible.
Table 1 Moxifloxacin IC50 values for various cardiac ionic currents
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of the day (4.00, 8.00, 12.00, 16.00, 20.00, and 24.00), were performed in triplicate trials
of 20 individuals (total 3×20=60) with an equal number of male and female subjects
(10/10 in each study). Baseline QT and QTcF (QT interval corrected by heart rate using
Fridericia correction method [30]) were also obtained for each subject at the above
defined time points of the day by simulating a response at MOXI concentration equal
to zero. This allowed us to apply two baseline correction formulas i.e., (1) Single point
baseline correction when the average baseline QTcF estimates from all subjects was
used to obtain baseline corrected QTcF (ΔQTcF) and (2) Individualised baseline correc-
tion (ΔQTcFi) when baseline QTcF at a given time of day for each individual subject
was used to calculate ΔQTcF. The developed circadian effect model was validated by
comparing the simulated results with respective clinical outcomes obtained using single
point and individualised baseline correction formula.
Results
Data modelling
The aim of this section is to describe the steps undertaken to create a multivari-
ate linear regression model of the relationship between RR (dependent variable)
and a set of independent variables which were comprised of Age, Sex and Time
of the day (abbreviated as Hour). In addition to the model development, the
simulation of RR values from the model was given attention. During the model
development phase it was found that the distribution of RR data was mildly
skewed to the right. This issue was dealt with the use of log-transformation of
RR measurements.
RR model
The preliminary model included dummy variables for each Hour, dummy variable for
Sex, quadratic effect of Age and all pairwise interactions. Many terms in this prelimin-
ary model were found not significant, as indicated by the robust t-tests for model
coefficients. The robust t-test takes into account the dependence between observations
coming from the same subject. Non-significant terms (p-value>0.05) were dropped
from the model sequentially one by one. Additionally it was found that the Hour vari-
able may be modelled more parsimoniously by a linear combination of sine and cosine
functions. The final model received the following form:




















 Sexþ ε; ε∼N 0; σð Þ;
ð2Þwhere:
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ε – normally distributed error term,
σ – standard deviation of error term,
Sex – 1 for males, 0 for females,
Age – age in years,
Hour – value from 0–24 range.
The model parameters were estimated using the maximum likelihood method in the
R system for statistical computing and are given below [31]:
^log RRð Þ ¼ 7:163þ 0:0961 Sex 0:0243 Age þ 0:00027 Age2


















All coefficients were statistically significant. Figure 1 shows the graphical representationof the model.
The visual predictive checks showed an overall good fit of the model to the data. The
dispersion of residuals did not exhibit dependence upon any of the explanatory
variables. The coefficient of determination R2 = 0.39, i.e. 39% of the variation observed
in log(RR) can be explained by the estimated regression equation.
For the PhysioNet data set RMSE (Root Mean Squared Error) = 128 ms and MAPE
(Mean Absolute Percentage Error) = 12.3%. In the case of the validation data set RMSE
= 165 ms and MAPE = 17.1%. Figure 2 shows the representative two best and two
worst fitted cases from the validation data set.
It is a well-known fact that estimators derived by the method of maximum likelihood
have many desirable properties, on the other hand ML estimators are sensitive to the
presence of outliers in the data. In order to check the stability of estimates the regres-
sion parameters were additionally estimated using a wide range of, so called, robust
regression estimators. Parameter estimates were virtually unchanged from the maximum
likelihood ones.
The residuals (ε̂) within each subject showed strong temporal dependence. Consequently




αp ε̂tp þ η; η∼N 0; τð Þ ð4Þ
where:
α – autoregression coefficient
η – normally distributed error term
τ – standard deviation of error term
P – order of autoregression
It was found that only a large value of P (P = 180) was able to account for the long
memory observed in the data and gives a satisfactory fit. The estimate of the standard
deviation of error term was 0.096.
Figure 1 Graphical representation of the RR model for females (A) and males (B) respectively, left
inner axis is age.
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estimated model:
1. Generate random sequence from equation [Eq. 4].
2. Choose the values of explanatory variables and using [Eq. 3] compute ^log RRð Þ at
the selected time points.
3. Add the computed ^log RRð Þ to values generated in Step 1 at the selected time
points, exponentiate the result.
An electronic supplement (Additional file 1) to the article contains a fully functional
Excel implementation of the model.
Figure 2 Representative two best (A - Female 41 years old, B - Male 36 years old) and two worst
(C - Female 27 years old, D - Male 30 years old) fitted cases from the validation data set (dashed
lines – 95% prediction bands).
Fijorek et al. Theoretical Biology and Medical Modelling 2013, 10:7 Page 8 of 11
http://www.tbiomed.com/content/10/1/7Model usability results
Figures 3 and 4 present the results of the model usability testing. Two sets of data
obtained after running the virtual study as described in the ‘Materials and methods’
section were obtained.
QT response at a MOXI concentration of 3.8 μM at different times of the day
was simulated using the ToxComp platform. When single point baseline correc-
tion was applied, the ΔQTcF obtained at different times of the day at a MOXI
concentration of 3.8 μM is shown in Figure 3. Generally, during TQT studies an
oral dose of MOXI 400 mg is given in the morning, hence Cmax is obtained
between morning and noon i.e. between 8.00 to 12.00. At 8.00 and 12.00, the
simulated ΔQTcF were respectively 10.75 ms and 15.87 ms, which is consistentFigure 3 ΔQTcF at MOXI concentration of 3.8 mM at different times of day presented as an average
value ±SD.
Figure 4 ΔQTcFi with individualized and circadian baseline correction presented as an average
value ±SD.
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baseline with circadian correction was applied, ΔQTcFi of 5–6 ms was obtained
at all times of day which is also consistent with the clinically observed ΔQTcFi of
6–7 ms [21].Discussion
The obtained results indicate that the implemented heart rate circadian rhythm
model within the ToxComp platform is able to simulate the circadian variability
of a model drug. Comparison with the published clinical trial results for the
model drug suggest that the ToxComp system, with the built-in heart rate model,
is able to realistically represent cardiac electrophysiological drug effect with its
variability, regardless of the correction method. However, as there are a large
number of parameters describing the physiological variability in the virtual popu-
lation generator ToxComp module, it is hard to precisely assess the net influence
of the heart rate on the system output, and a separate study will be run for such
a purpose. Although results of the simulations run without the use of a heart rate
model, i.e. with the use of a constant value of HR during the day, suggested that
an important component is missing (internal not-published results).
The goodness-of-fit metrics indicated a good fit to the data, e.g. Mean Absolute Per-
centage Error equals to 12.3%. It could, although, suggest that the model overfits the
data. This was however contradicted by the validation results with MAPE equals to
17.1%. The result was obtained despite the differences in the age and sex distribution
of the subjects between the training and validation data sets.
The main limitation of the model is the size of the training data set. Despite
the fact that every subject gave rise to thousands of measurements, the number
of independent subjects is still only 18. The future research will aim to combine
data from experiments which acquire sparse RR data, e.g. every 20–40 minutes,
with dense PhysioBank data.
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It can be concluded that a flexible and practically useful model describing the
heart rate circadian variation has been developed. Its structure allows for easy
implementation, which is greatly facilitated by the provided electronic supplement,
and its use in simulation studies.
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